MedWatch

New attack on clinical research in Denmark: It is way too expensive

Even though the fees for clinical research have been lowered, it is still so expensive to conduct studies on new drugs in Denmark that it threatens future studies according to several representatives from the industry. Danish Regions believes that the industry should accept its share of the payment.

Foto: Colourbox

It has been said time and time again that it is too expensive to conduct clinical trials in Denmark.

Nevertheless, it caused a stir when Dorte Klokker, Head of Clinical Operations at Roche, criticized the costs of clinical trials in Science Report.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Headhunter: Afgående Leo-boss var et flop

Det var et fejlskud at ansætte Catherine Mazzacco som adm. direktør for Leo Pharma, vurderer headhunter, der ser afgangen som et naturligt skridt forud for børsnoteringen af Leo Pharma. Til at styre den proces i mål vil bestyrelsen efter alt at dømme skulle til udlandet for at finde den rette profil, lyder det videre.

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier